67437-93-8

Basic information

• Product Name: 1,3-Dioxane,2-(3-bromophenyl)-(9CI)
• Synonyms: 1,3-Dioxane,2-(3-bromophenyl)-(9CI)
• CAS NO: 67437-93-8
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.09714
• Product Categories: PHENYL
• Mol File: 67437-93-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-Dioxane,2-(3-bromophenyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxane,2-(3-bromophenyl)-(9CI)(67437-93-8)
• EPA Substance Registry System: 1,3-Dioxane,2-(3-bromophenyl)-(9CI)(67437-93-8)

Safety Data

• Hazardous Substances Data: 67437-93-8(Hazardous Substances Data)

Usage

General Description

1,3-Dioxane,2-(3-bromophenyl)-(9CI) is an organic compound with the molecular formula C9H9BrO2. It is a colorless liquid that is commonly used as a solvent and in the production of various chemicals and pharmaceuticals. 1,3-Dioxane,2-(3-bromophenyl)-(9CI) is also known to be a potential environmental contaminant and has been linked to health concerns due to its potential carcinogenic properties. It is important to handle and use this chemical with caution and follow proper safety measures to minimize environmental and health risks.

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 504-63-2 trimethyleneglycol 

Downstream Products

• 79124-76-8 3-(3,4-dichlorophenoxy)benzaldehyde 
• 79124-75-7 3-(4-methylphenoxy)-benzaldehyde 
• 62373-80-2 3-(4-methoxyphenoxy)benzaldehyde 
• 69770-20-3 3-(4-chlorophenoxy)benzaldehyde 
• 1610379-58-2 3-(4-isopropylpiperazin-1-yl)benzaldehyde 
• 1023888-04-1 C₁₄H₁₇NO₂ 
• 1025998-61-1 (E)-7-[4-(3-[1,3]Dioxan-2-yl-benzyloxy)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid ethyl ester 
• 1026698-04-3 ethyl (E)-7-<4-<(3-formylphenyl)methoxy>phenyl>-7-(3-pyridyl)hept-6-enoate 
• 163164-08-7 2-<3-(hydroxymethyl)phenyl>-1,3-dioxane 
• 853944-39-5 1-[3-(tert-butyldimethylsilyloxymethyl)-phenyl]-1-phenylethylene 

Relevant articles and documents

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Mycobacterium tuberculosis thymidylate kinase (MtTMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside MtTMPK inhibitors in an effort to diversify MtTMPK inhibitor chemical space. We here report a new series of MtTMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by two co-crystal structures of MtTMPK in complex with developed inhibitors. These efforts furnished the most potent MtTMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the MtTMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.

CYCLIC AMINES AS BROMODOMAIN INHIBITORS

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.